Correlation between p53 gene mutation, p53 protein labeling and PCNA expression in oral squamous cell carcinomas

Loading...
Thumbnail Image

Authors

Van Heerden, Willem Francois Petrus
Janse van Rensburg, Estrelita
Hemmer, J.
Raubenheimer, E.J.
Engelbrecht, Susan

Journal Title

Journal ISSN

Volume Title

Publisher

International Institute of Anticancer Research

Abstract

The prevalence of oral squamous cell carcinoma (OSCC) among the black community in South Africa is unacceptably high. The association between p53 protein, and PCNA overexpression and the presence of p53 gene mutations was evaluated. Materials and Methods: One hundred and ten formalin-fixed, paraffin-embedded blocks of OSCC were selected for immunohistochemical studies for p53 protein and PCNA expression using the DO-7 and PC10 monoclonal antibodies, respectively. DNA was extracted from fifty-five block and exons 5 to 9 of the p53 gene were amplified with nested primers, thereafter sequencing was performed to confirm the presence of mutations detected by single stranded conformational polymorphism. Results: Fifty-six cases (51%) showed p53 expression, while fourteen mutations (25%) were detected. A significant difference was found between the PCNA index in p53 positive and p53 negative rumors while the mean PCNA index for the tumors with p53 mutations was not significantly different from the tumors without mutations. Conclusions: No association between p53 protein overexpression and p53 gene mutations could be demonstrated.

Description

The article was co-written by Prof Janse van Rensburg before she joined the University of Pretoria.

Keywords

Nuclear antigen, Flow-cytometry, Proliferation, Overexpression, Oncoprotein, Cancer, Cyclin, Oral cancer, P53

Sustainable Development Goals

Citation

Van Heerden, WFP, Janse van Rensburg, E, Hemmer, J, Raubenheimer, EJ & Engelbrecht, S 1998,'Correlation between p53 gene mutation, p53 protein labeling and PCNA expression in oral squamous cell carcinomas', Anticancer Research, vol. 18, no. 1A, pp. 237-240. [http://www.iiar-anticancer.org/index2.htm]